The authors would like to correct the errors in the publication of the original article. The correction details are given below.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12185-019-02663-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Pharmacogenomics of Drugs Used in β-Thalassemia and Sickle-Cell Disease: From Basic Research to Clinical Applications.
Int J Mol Sci
April 2024
Implementing Sustainable Evidence-Based Interventions through Engagement (ISEE) Lab, Department of Global and Environmental Health, School of Global Public Health, New York University, New York, NY 10003, USA.
In this short review we have presented and discussed studies on pharmacogenomics (also termed pharmacogenetics) of the drugs employed in the treatment of β-thalassemia or Sickle-cell disease (SCD). This field of investigation is relevant, since it is expected to help clinicians select the appropriate drug and the correct dosage for each patient. We first discussed the search for DNA polymorphisms associated with a high expression of γ-globin genes and identified this using GWAS studies and CRISPR-based gene editing approaches.
View Article and Find Full Text PDFBelantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial.
Nat Med
February 2024
Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada.
Due to evolving treatment standards for newly diagnosed multiple myeloma, many patients will be triple-class exposed after initial relapses and have poor survival. Novel therapies and combinations are therefore required to improve outcomes. B cell maturation antigen (BCMA)-targeted biologics have emerged as an important new area of therapeutics for relapsed multiple myeloma.
View Article and Find Full Text PDFSystemic lupus erythematosus combined with Castleman disease and secondary paraneoplastic pemphigus: a case report.
Pediatr Rheumatol Online J
October 2023
Department of Rheumatology and Immunology, The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology, No,24 Jinghua Road, Luoyang, China.
Article Synopsis
- - A 12-year-old girl with systemic lupus erythematosus (SLE) presented symptoms like neck mass, rash, and mouth ulcers, along with low blood cell counts and multiple autoantibodies.
- - The neck mass was diagnosed as Castleman's disease (CD), and skin examination revealed secondary paraneoplastic pemphigus (PNP).
- - Treatment included various medications and surgery to remove the neck mass, leading to stable disease status with no recurrence of skin lesions during follow-up.
Using the "periodic confirmation sheet" employed in the safety management procedure of thalidomide drugs, we looked at whether patients' knowledge of compliance with the procedure varies depending on the length of the gap between confirmations. In 31 centers, 215 participants were male patients and female patients who might be pregnant participants. Subjects have treated a group of patients who used periodic confirmation slips at the standard confirmation interval and a group of patients who increase the confirmation interval to 4 or 6 months, the % of respondents that correctly answered each of all six questions in questions 1-6 on the second comprehension questionnaire, excluding question 7 to confirm behavior change, was 87.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!